Imprimis Pharmaceuticals Company Profile (NASDAQ:IMMY)

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals logoImprimis Pharmaceuticals, Inc. (Imprimis) is engaged in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IMMY
  • CUSIP:
Key Metrics:
  • Previous Close: $2.54
  • 50 Day Moving Average: $2.49
  • 200 Day Moving Average: $3.01
  • 52-Week Range: $1.65 - $4.90
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.94
  • P/E Growth: -0.14
  • Market Cap: $33.66M
  • Outstanding Shares: 13,253,000
  • Beta: 0.61
Profitability:
  • Net Margins: -102.59%
  • Return on Equity: -457.59%
  • Return on Assets: -87.29%
Debt:
  • Debt-to-Equity Ratio: 3.94%
  • Current Ratio: 1.55%
  • Quick Ratio: 1.22%
Additional Links:
Companies Related to Imprimis Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Imprimis Pharmaceuticals (NASDAQ:IMMY) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.00 (92.31% upside)

Analysts' Ratings History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Show:
DateFirmActionRatingPrice TargetDetails
11/28/2016HC WainwrightInitiated CoverageBuy$5.00View Rating Details
11/28/2016Rodman & RenshawInitiated CoverageBuy$5.00View Rating Details
7/23/2015Sterne Agee CRTInitiated CoverageBuy$10.00View Rating Details
(Data available from 2/21/2015 forward)

Earnings

Earnings History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/21/2017        
8/15/2016Q216($0.35)$4.53 million$4.90 millionViewListenView Earnings Details
5/12/2016Q116($0.27)($0.43)$3.24 million$4.40 millionViewListenView Earnings Details
3/23/2016Q415($0.26)($0.31)$3.52 million$3.50 millionViewListenView Earnings Details
11/12/2015Q3($0.38)($0.25)ViewListenView Earnings Details
8/12/2015Q215($0.33)($0.39)$2.13 million$2.00 millionViewListenView Earnings Details
5/13/2015Q115($0.25)($0.33)$1.55 million$16.00 millionViewN/AView Earnings Details
3/12/2015Q414($0.25)($0.30)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Current Year EPS Consensus Estimate: $-1.32 EPS
Next Year EPS Consensus Estimate: $-0.66 EPS

Dividends

Dividend History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Imprimis Pharmaceuticals (NASDAQ:IMMY)
Insider Ownership Percentage: 14.59%
Institutional Ownership Percentage: 25.14%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/19/2016Andrew R BollCFOBuy39,000$1.79$69,810.00View SEC Filing  
12/19/2016Mark L BaumCEOBuy156,000$1.79$279,240.00View SEC Filing  
12/19/2016Richard L Md LindstromDirectorBuy100,000$1.79$179,000.00View SEC Filing  
3/11/2016Opaleye Management Inc.Major ShareholderBuy45,000$3.65$164,250.00View SEC Filing  
6/30/2015Opaleye Management Inc.Major ShareholderBuy35,000$7.90$276,500.00View SEC Filing  
5/19/2015Donald Paul MiloniMajor ShareholderSell410,000$8.00$3,280,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Imprimis Pharmaceuticals (NASDAQ:IMMY)
DateHeadline
fxpips.com logoComposite Trading’s Biggest Declining Shares, Feb. 20 (NASDAQ:IMMY)
www.fxpips.com - February 20 at 10:38 AM
marketexclusive.com logoIMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Files An 8-K Results of Operations and Financial Condition (NASDAQ:IMMY)
marketexclusive.com - February 18 at 10:56 AM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisit (NASDAQ:IMMY)
biz.yahoo.com - February 17 at 5:32 PM
finance.yahoo.com logoImprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility (NASDAQ:IMMY)
finance.yahoo.com - February 16 at 8:12 AM
News IconImprimis Pharmaceuticals Inc. (IMMY) Receives Consensus Rating of "Strong Buy" from Analysts (NASDAQ:IMMY)
flapship.com - January 25 at 7:17 PM
capitalcube.com logoETFs with exposure to Imprimis Pharmaceuticals, Inc. : January 20, 2017 (NASDAQ:IMMY)
www.capitalcube.com - January 20 at 3:27 PM
News IconBargain or Bait? Stock Update on Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) - Prospect Journal (NASDAQ:IMMY)
prospectjournal.com - January 14 at 5:12 AM
News IconPrice Action To Observe: Imprimis Pharmaceuticals Inc Can't Burn Your Long Portfolio. Has Another Strong Session - Fair View Times (NASDAQ:IMMY)
fairviewtimes.com - January 13 at 7:08 PM
investornewswire.com logoImprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) Strong Sell Recommendations At {RATING_CNT_STRONG_SELLS ... - Investor Newswire (NASDAQ:IMMY)
www.investornewswire.com - January 12 at 4:36 AM
News IconAre There Any Catalysts to Propel Shares of Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) - Prospect Journal (NASDAQ:IMMY)
prospectjournal.com - January 12 at 4:36 AM
News IconPrimed for Breakout or Bust? A look at Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) - Prospect Journal (NASDAQ:IMMY)
prospectjournal.com - January 10 at 11:49 PM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct F (NASDAQ:IMMY)
biz.yahoo.com - January 4 at 2:00 AM
marketexclusive.com logoIMPRIMIS PHARMACEUTICALS, INC. (NASDAQ:IMMY) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:IMMY)
marketexclusive.com - December 29 at 5:57 PM
4-traders.com logoImprimis Pharmaceuticals Inc. : (IMMY) CFO Acquires $69,810.00 in Stock (NASDAQ:IMMY)
www.4-traders.com - December 27 at 10:57 AM
4-traders.com logoImprimis Pharmaceuticals : Mark L. Baum Purchases 156,000 Shares of Imprimis Pharmaceuticals Inc. Stock (NASDAQ:IMMY)
www.4-traders.com - December 24 at 5:42 AM
capitalcube.com logoETFs with exposure to Imprimis Pharmaceuticals, Inc. : December 23, 2016 (NASDAQ:IMMY)
www.capitalcube.com - December 23 at 6:08 PM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of E (NASDAQ:IMMY)
biz.yahoo.com - December 23 at 6:08 PM
finance.yahoo.com logoImprimis Pharmaceuticals Inc (IMMY) CEO Mark L Baum Bought $279,240 of Shares (NASDAQ:IMMY)
finance.yahoo.com - December 21 at 6:45 PM
finance.yahoo.com logoImprimis Pharmaceuticals and FocusScript Partner to Exclusively Offer the Correct Compound™ Program (NASDAQ:IMMY)
finance.yahoo.com - December 21 at 9:17 AM
streetinsider.com logoImprimis Pharma (IMMY) Reports $9.8M Private Placement of Common stock and Warrants (NASDAQ:IMMY)
www.streetinsider.com - December 20 at 11:17 AM
finance.yahoo.com logoImprimis Pharmaceuticals Announces $9.8 Million Private Placement of Units (NASDAQ:IMMY)
finance.yahoo.com - December 20 at 11:17 AM
finance.yahoo.com logo4:31 pm Imprimis Pharmaceuticals enters into a definitive securities purchase agreement with various accredited investors and certain members of Imprimis' Board of Directors and senior management to raise gross proceeds of approx. $9.8 mill (NASDAQ:IMMY)
finance.yahoo.com - December 20 at 11:17 AM
4-traders.com logoImprimis Pharmaceuticals : Immy) Given Consensus Rating of Strong Buy by the Brokerages (NASDAQ:IMMY)
www.4-traders.com - December 15 at 11:32 PM
capitalcube.com logoETFs with exposure to Imprimis Pharmaceuticals, Inc. : December 12, 2016 (NASDAQ:IMMY)
www.capitalcube.com - December 12 at 6:00 PM
finance.yahoo.com logoImprimis CEO Talks Phenomenal Quarter: 'Shocking' Statistics, Simplification And A Trifecta For Success (NASDAQ:IMMY)
finance.yahoo.com - December 1 at 5:53 PM
finance.yahoo.com logoCoverage initiated on Imprimis Pharmaceuticals by Rodman & Renshaw (NASDAQ:IMMY)
finance.yahoo.com - November 29 at 4:34 PM
capitalcube.com logoETFs with exposure to Imprimis Pharmaceuticals, Inc. : November 28, 2016 (NASDAQ:IMMY)
www.capitalcube.com - November 29 at 4:34 PM
News IconVideo-Big Pharma Prioritises Profits Over Patients | Mark Baum | Oxford Union for Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY)
www.companyspotlight.com - November 29 at 4:34 PM
News IconImprimis Pharmaceuticals, Inc. IMMY Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:IMMY)
www.bioportfolio.com - November 25 at 10:51 AM
capitalcube.com logoImprimis Pharmaceuticals, Inc. :IMMY-US: Earnings Analysis: Q3, 2016 By the Numbers : November 23, 2016 (NASDAQ:IMMY)
www.capitalcube.com - November 23 at 5:41 PM
News IconPredicting Top 4 Teams After Week 11 Action (NASDAQ:IMMY)
avauncer.com - November 19 at 8:10 AM
finance.yahoo.com logoImprimis Pharmaceuticals Ranked 12 on Deloitte's 2016 Technology Fast 500™ List of Fastest Growing Companies in North America (NASDAQ:IMMY)
finance.yahoo.com - November 17 at 8:53 AM
4-traders.com logoImprimis Pharmaceuticals : reports 3Q loss (NASDAQ:IMMY)
www.4-traders.com - November 16 at 5:52 PM
finance.yahoo.com logoImprimis Pharmaceuticals Announces Third Quarter 2016 Financial Results (NASDAQ:IMMY)
finance.yahoo.com - November 16 at 5:52 PM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Discl (NASDAQ:IMMY)
biz.yahoo.com - November 15 at 9:09 AM
sg.finance.yahoo.com logoImprimis reports 3Q loss (NASDAQ:IMMY)
sg.finance.yahoo.com - November 14 at 5:51 PM
sg.finance.yahoo.com logoImprimis reports 3Q loss (NASDAQ:IMMY)
sg.finance.yahoo.com - November 14 at 5:51 PM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:IMMY)
biz.yahoo.com - November 14 at 5:51 PM
biz.yahoo.com logoIMPRIMIS PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:IMMY)
biz.yahoo.com - November 14 at 5:51 PM
biz.yahoo.com logoQ3 2016 Imprimis Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:IMMY)
biz.yahoo.com - November 14 at 9:41 AM
finance.yahoo.com logoInvestor Calendar Invites You to the Imprimis Pharmaceuticals Third Quarter 2016 Earnings Conference Call and Webcast Live on Monday, November 14, 2016 (NASDAQ:IMMY)
finance.yahoo.com - November 14 at 9:41 AM
finance.yahoo.com logoImprimis Pharmaceuticals Signs Agreement with Specialty Pharmacy Division of One of the Nation's Largest Pharmacy Benefit Managers (NASDAQ:IMMY)
finance.yahoo.com - November 13 at 9:43 AM
streetinsider.com logoImprimis Pharma (IMMY) Enters Purchase, Supply Agreement with Large PBM Unit (NASDAQ:IMMY)
www.streetinsider.com - November 10 at 5:02 PM
finance.yahoo.com logoImprimis Pharmaceuticals to Host its Third Quarter 2016 Financial Report (NASDAQ:IMMY)
finance.yahoo.com - November 3 at 9:06 AM
finance.yahoo.com logoImprimis Pharmaceuticals Registers its New Jersey Facility with the FDA as an Outsourcing Facility (NASDAQ:IMMY)
finance.yahoo.com - October 28 at 8:58 AM
finance.yahoo.com logoImprimis' Dropless Therapy Shows Significant Advantages in a Large Peer-Reviewed Study (NASDAQ:IMMY)
finance.yahoo.com - October 25 at 5:40 PM
finance.yahoo.com logoImprimis Pharmaceuticals Announces Availability of Lower-Cost Option for the Treatment of Lead Poisoning (NASDAQ:IMMY)
finance.yahoo.com - October 17 at 5:34 PM
streetinsider.com logoImprimis Pharma (IMMY) Announces Lower-Cost Option to Valeant's (VRX) Lead Poisoning Treatment (NASDAQ:IMMY)
www.streetinsider.com - October 17 at 5:34 PM
finance.yahoo.com logoImprimis Pharmaceuticals' Formulations to be Highlighted at Upcoming Annual Ophthalmology Meeting in Chicago (NASDAQ:IMMY)
finance.yahoo.com - October 13 at 8:53 AM
finance.yahoo.com logoImprimis Pharmaceuticals' CEO Mark L. Baum to Debate at the Oxford Union Debating Society (NASDAQ:IMMY)
finance.yahoo.com - October 6 at 10:57 AM

Social

What is Imprimis Pharmaceuticals' stock symbol?

Imprimis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMMY."

Where is Imprimis Pharmaceuticals' stock going? Where will Imprimis Pharmaceuticals' stock price be in 2017?

2 brokers have issued 12-month target prices for Imprimis Pharmaceuticals' stock. Their predictions range from $5.00 to $5.00. On average, they expect Imprimis Pharmaceuticals' stock price to reach $5.00 in the next year.

When will Imprimis Pharmaceuticals announce their earnings?

Imprimis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 21st 2017.

Who owns Imprimis Pharmaceuticals stock?

Imprimis Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Opaleye Management Inc. (5.43%) and Bard Associates Inc. (0.49%). Company insiders that own Imprimis Pharmaceuticals stock include Andrew R Boll, Donald Paul Miloni, Mark L Baum, Opaleye Management Inc and Richard L Md Lindstrom.

Who sold Imprimis Pharmaceuticals stock? Who is selling Imprimis Pharmaceuticals stock?

Imprimis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc. and Bard Associates Inc..

How do I buy Imprimis Pharmaceuticals stock?

Shares of Imprimis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Imprimis Pharmaceuticals stock cost?

One share of Imprimis Pharmaceuticals stock can currently be purchased for approximately $2.60.

Imprimis Pharmaceuticals (NASDAQ:IMMY) Chart for Tuesday, February, 21, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Earnings History Chart

Earnings by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Dividend History Chart

Dividend Payments by Quarter for Imprimis Pharmaceuticals (NASDAQ:IMMY)

Last Updated on 2/21/2017 by MarketBeat.com Staff